By the end of 2017, CTS has secured three source plasma partners and continues to seek additional partners in the plasma industry in order to continue to diversify CTS’s revenue stream.
CTS Tampa lab implements Dengue testing on behalf of a healthcare partner in an endemic area.
In January, CTS is incorporated as a non-profit organization owned by Vitalant and OneBlood (formerl...
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...
CTS Tampa lab implemented the Ortho Clinical Diagnostics VITROS® testing platform to perform COVID-1...
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).